Company intelligence / Profile preview

Standard Bariatrics

Cincinnati, Ohio, United Statesstandardbariatrics.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s lead product, the Titan SGS stapling device for sleeve gastrectomy, received FDA clearance in April 2021 and has been used successfully across multiple states. Clinical studies have demonstrated its ability to deliver consistent staple lines and improved outcomes in bariatric surgery. The company reached significant sales milestones prior to acquisition by Teleflex.

Therapeutic areas: Metabolic Disorders
Modalities: Device (surgical stapler and related tools)Non-pharmacological therapy (bariatric surgery support devices)
Industry: Surgical Medical Devices

Partnerships

No major external pharma/biotech partnerships disclosed pre-acquisition; supported by investors such as RiverVest, River Cities Capital, Hatteras Venture Partners, Emergent Medical Partners, USVP

Beyond the preview

Go deeper on Standard Bariatrics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Standard Bariatrics.

Explore the full profile